US20040152745A1
(en)
*
|
1999-11-12 |
2004-08-05 |
Guilford Pharmaceuticals, Inc. |
Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
|
UA82048C2
(uk)
|
2000-11-10 |
2008-03-11 |
Эли Лилли Энд Компани |
Агоністи альфа-рецепторів, активованих проліфератором пероксисом
|
NZ529973A
(en)
|
2001-06-27 |
2006-01-27 |
Smithkline Beecham Corp |
Fluoropyrrolidines as dipeptidyl peptidase inhibitors
|
JP4300108B2
(ja)
|
2001-06-27 |
2009-07-22 |
スミスクライン ビーチャム コーポレーション |
ジペプチジルペプチダーゼ阻害剤としてのピロリジン類
|
EP1399433B1
(de)
|
2001-06-27 |
2007-08-22 |
Smithkline Beecham Corporation |
Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren
|
DE60304911D1
(de)
|
2002-02-25 |
2006-06-08 |
Eisai Co Ltd |
Xanthin-Derivate als DPP-IV-Inhibitoren
|
US7405234B2
(en)
*
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
WO2004045518A2
(en)
*
|
2002-11-15 |
2004-06-03 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
AU2003294824A1
(en)
*
|
2002-12-10 |
2004-06-30 |
Novartis Ag |
Combination of an dpp-iv inhibitor and a ppar-alpha compound
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
AU2004210149A1
(en)
*
|
2003-01-31 |
2004-08-19 |
Merck & Co., Inc. |
3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
US20060142356A1
(en)
*
|
2003-02-17 |
2006-06-29 |
Davis Adrian F |
Novel therapeutic method and compositions for topical administration
|
GB0303600D0
(en)
*
|
2003-02-17 |
2003-03-19 |
Glaxo Group Ltd |
Novel therapeutic method and compositions
|
CN1894234A
(zh)
|
2003-03-25 |
2007-01-10 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
ATE464889T1
(de)
|
2003-05-05 |
2010-05-15 |
Probiodrug Ag |
Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
|
DE602004026712D1
(de)
|
2003-05-05 |
2010-06-02 |
Probiodrug Ag |
Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen
|
JP4806628B2
(ja)
|
2003-05-05 |
2011-11-02 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤
|
JP2007511467A
(ja)
|
2003-05-14 |
2007-05-10 |
タケダ サン ディエゴ インコーポレイテッド |
ジペプチジルペプチダーゼインヒビター
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7723344B2
(en)
|
2003-08-13 |
2010-05-25 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
JP2007502991A
(ja)
|
2003-08-20 |
2007-02-15 |
バイオサイト インコーポレイテッド |
生物活性ナトリウム利尿ペプチドを測定するための、およびその治療可能性を向上させるための方法および組成物
|
EP1699777B1
(de)
|
2003-09-08 |
2012-12-12 |
Takeda Pharmaceutical Company Limited |
Dipeptidylpeptidase-hemmer
|
ATE547404T1
(de)
|
2003-09-22 |
2012-03-15 |
Msd Kk |
Piperidinderivate
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
WO2005030185A2
(en)
|
2003-09-26 |
2005-04-07 |
Japan Tobacco Inc. |
Method of inhibiting remnant lipoprotein production
|
MXPA06003998A
(es)
|
2003-10-15 |
2006-06-27 |
Probiodrug Ag |
Uso de efectores de ciclasas de glutamato y glutaminil.
|
US20050137142A1
(en)
|
2003-11-03 |
2005-06-23 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
US20070149451A1
(en)
*
|
2003-11-17 |
2007-06-28 |
Holmes David G |
Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
|
WO2005049022A2
(en)
|
2003-11-17 |
2005-06-02 |
Novartis Ag |
Use of dipeptidyl peptidase iv inhibitors
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
EP1541148A1
(de)
*
|
2003-12-09 |
2005-06-15 |
Graffinity Pharmaceuticals Aktiengesellschaft |
Dpp-iv inhibitoren
|
EP1541143A1
(de)
*
|
2003-12-09 |
2005-06-15 |
Graffinity Pharmaceuticals Aktiengesellschaft |
Dpp-iv inhibitoren
|
SI3366283T1
(sl)
|
2004-01-20 |
2021-12-31 |
Novartis Ag |
Formulacija za neposredno stiskanje in postopek
|
AU2005210004B2
(en)
|
2004-02-05 |
2010-10-28 |
Probiodrug Ag |
Novel inhibitors of glutaminyl cyclase
|
US7388027B2
(en)
*
|
2004-03-04 |
2008-06-17 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
CN102134230B
(zh)
|
2004-03-15 |
2019-06-28 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
CN1938286A
(zh)
|
2004-03-29 |
2007-03-28 |
默克公司 |
作为11-β-羟甾类脱氢酶-1抑制剂的二芳基三唑
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
US7687638B2
(en)
*
|
2004-06-04 |
2010-03-30 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
WO2006019965A2
(en)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
ATE553077T1
(de)
*
|
2004-07-23 |
2012-04-15 |
Nuada Llc |
Peptidaseinhibitoren
|
CA2575736A1
(en)
|
2004-08-06 |
2006-02-16 |
Merck & Co., Inc. |
Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
|
US7732472B2
(en)
*
|
2004-08-18 |
2010-06-08 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
WO2006047248A1
(en)
*
|
2004-10-25 |
2006-05-04 |
Novartis Ag |
Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
|
EP1828192B1
(de)
*
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidylpeptidasehemmer
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
EP1846410B1
(de)
*
|
2005-02-10 |
2009-01-21 |
Bristol-Myers Squibb Company |
Dihydrochinazolinone als 5ht-modulatoren
|
US8138206B2
(en)
|
2005-05-30 |
2012-03-20 |
Msd. K.K. |
Piperidine derivative
|
US20090317376A1
(en)
|
2005-06-06 |
2009-12-24 |
Georgetown University Medical School |
Compositions And Methods For Lipo Modeling
|
GT200600218A
(es)
*
|
2005-06-10 |
2007-03-28 |
|
Formulación y proceso de compresión directa
|
JP2009502959A
(ja)
*
|
2005-07-28 |
2009-01-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−1h−ピリド[4,3,b]インドール
|
WO2007018248A1
(ja)
|
2005-08-10 |
2007-02-15 |
Banyu Pharmaceutical Co., Ltd. |
ピリドン化合物
|
US7875633B2
(en)
|
2005-08-24 |
2011-01-25 |
Banyu Pharmaceutical Co., Ltd. |
Phenylpyridone derivative
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
WO2007029847A1
(ja)
|
2005-09-07 |
2007-03-15 |
Banyu Pharmaceutical Co., Ltd. |
二環性芳香族置換ピリドン誘導体
|
SI1942898T2
(sl)
|
2005-09-14 |
2014-08-29 |
Takeda Pharmaceutical Company Limited |
Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa
|
PE20070622A1
(es)
*
|
2005-09-14 |
2007-08-22 |
Takeda Pharmaceutical |
Administracion de inhibidores de dipeptidil peptidasa
|
CN102675221A
(zh)
|
2005-09-16 |
2012-09-19 |
武田药品工业株式会社 |
用于制备嘧啶二酮衍生物的方法中的中间体
|
JP4879988B2
(ja)
|
2005-09-29 |
2012-02-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
|
WO2007049798A1
(ja)
|
2005-10-27 |
2007-05-03 |
Banyu Pharmaceutical Co., Ltd. |
新規ベンゾオキサチイン誘導体
|
AU2006312557B2
(en)
|
2005-11-10 |
2011-12-08 |
Msd K.K. |
Aza-substituted spiro derivative
|
EP1801098A1
(de)
|
2005-12-16 |
2007-06-27 |
Merck Sante |
2-Adamantylharnstoff Derivative als selektive 11B-HSD1 Inhibitoren
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
WO2007112347A1
(en)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
DK1971862T3
(da)
|
2006-04-11 |
2011-02-14 |
Arena Pharm Inc |
Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
|
BRPI0709984A2
(pt)
|
2006-04-12 |
2011-08-02 |
Probiodrug Ag |
inibidores de enzima
|
PT2073810E
(pt)
*
|
2006-09-13 |
2011-09-30 |
Takeda Pharmaceutical |
Utilização de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo- 3,4-di-hidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo para tratamento de diabetes, cancro, distúrbios auto-imunes e infecção por vih
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
EP2946778A1
(de)
|
2006-09-22 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Behandlungsverfahren mit verwendung von fettsäuresyntheseinhibitoren
|
AU2007301126A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
EP2089383B1
(de)
|
2006-11-09 |
2015-09-16 |
Probiodrug AG |
3-hydroxy-1,5-dihydropyrrol-2-one derivate als inhibitoren von glutaminylcyclase zur behandlung von geschwüren, krebs und anderen krankheiten
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
US9126987B2
(en)
|
2006-11-30 |
2015-09-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
EP1935420A1
(de)
|
2006-12-21 |
2008-06-25 |
Merck Sante |
2-Adamantyl-Butyramid Derivate als selektive 11Beta-HSD1 Inhibitoren
|
TW201350143A
(zh)
|
2007-02-01 |
2013-12-16 |
Takeda Pharmaceutical |
固體型製劑
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
JP5319518B2
(ja)
|
2007-04-02 |
2013-10-16 |
Msd株式会社 |
インドールジオン誘導体
|
KR20120030570A
(ko)
|
2007-04-03 |
2012-03-28 |
미쓰비시 타나베 파마 코퍼레이션 |
디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용
|
US9656991B2
(en)
|
2007-04-18 |
2017-05-23 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
CA2688187C
(en)
|
2007-05-07 |
2016-10-11 |
Merck & Co., Inc. |
Method of treament using fused aromatic compounds having anti-diabetic activity
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
US20110015181A1
(en)
|
2008-03-06 |
2011-01-20 |
Makoto Ando |
Alkylaminopyridine derivative
|
US20110015198A1
(en)
|
2008-03-28 |
2011-01-20 |
Banyu Pharmaceutical Co., Inc. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
EP2108960A1
(de)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY
|
EP2110374A1
(de)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofuran, Benzothiophen, Benzothiazolderivate als FXR-Modulatoren
|
EP2328910B1
(de)
|
2008-06-04 |
2014-08-06 |
Synergy Pharmaceuticals Inc. |
Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
|
CA2727914A1
(en)
|
2008-06-19 |
2009-12-23 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diaryl ketoxime derivative technical field
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
AU2009277736A1
(en)
|
2008-07-30 |
2010-02-04 |
Banyu Pharmaceutical Co., Ltd. |
(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
|
CA2741125A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US8592457B2
(en)
|
2008-10-30 |
2013-11-26 |
Merck Sharp & Dohme Corp. |
Isonicotinamide orexin receptor antagonists
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
ES2614427T3
(es)
|
2008-11-07 |
2017-05-31 |
The General Hospital Corporation |
Fragmentos C-terminales de péptido glucagonoide 1 (GLP-1)
|
WO2010056717A1
(en)
|
2008-11-17 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
US20120220567A1
(en)
|
2009-07-23 |
2012-08-30 |
Shipps Jr Gerald W |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
PL2475428T3
(pl)
|
2009-09-11 |
2015-12-31 |
Probiodrug Ag |
Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
|
JP2013510834A
(ja)
|
2009-11-16 |
2013-03-28 |
メリテク |
[1,5]‐ジアゾシン誘導体
|
EP2521721B1
(de)
|
2009-12-30 |
2014-10-01 |
Shanghai Fochon Pharmaceutical Co. Ltd |
3-(3-aminopiperidin-1-yl)-5-oxo-1,2,4-triazin-derivate als dipeptidyl-peptidase iv (dpp iv)-hemmer
|
CA2786314A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
US9181233B2
(en)
|
2010-03-03 |
2015-11-10 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
DK2545047T3
(da)
|
2010-03-10 |
2014-07-28 |
Probiodrug Ag |
Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
|
EP2556056A1
(de)
|
2010-04-06 |
2013-02-13 |
Arena Pharmaceuticals, Inc. |
Modulatoren des gpr119-rezeptors und behandlung von damit assoziierten erkrankungen
|
WO2011131748A2
(en)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Novel inhibitors
|
WO2012027331A1
(en)
|
2010-08-27 |
2012-03-01 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012040279A1
(en)
|
2010-09-22 |
2012-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
WO2012061466A2
(en)
|
2010-11-02 |
2012-05-10 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
PE20140859A1
(es)
|
2011-02-25 |
2014-07-25 |
Merck Sharp & Dohme |
Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos
|
CA3100941C
(en)
|
2011-03-01 |
2024-03-05 |
Synergy Pharmaceuticals Inc. |
Process of preparing guanylate cyclase c agonists
|
EP2686313B1
(de)
|
2011-03-16 |
2016-02-03 |
Probiodrug AG |
Benzimidazolderivate als glutaminylcyclase-hemmer
|
US20140018371A1
(en)
|
2011-04-01 |
2014-01-16 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
US20140066369A1
(en)
|
2011-04-19 |
2014-03-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
US20140051714A1
(en)
|
2011-04-22 |
2014-02-20 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
US20140038889A1
(en)
|
2011-04-22 |
2014-02-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012170702A1
(en)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
EP2729157B1
(de)
|
2011-07-06 |
2019-01-16 |
The General Hospital Corporation |
Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung
|
WO2013055910A1
(en)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
BR112015002080A2
(pt)
|
2012-08-02 |
2017-07-04 |
Merck Sharp & Dohme |
composto, composição farmacêutica, uso de um composto, e, método de tratamento ou de prevenção de um transtorno, de uma condição ou de uma doença
|
WO2014074668A1
(en)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulators of gpr119 and the treatment of disorders related thereto
|
EP2958562A4
(de)
|
2013-02-22 |
2016-08-10 |
Merck Sharp & Dohme |
Antidiabetische bicyclische verbindungen
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
EP2968439A2
(de)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Zusammensetzungen zur behandlung von magen-darm-störungen
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
US10011637B2
(en)
|
2013-06-05 |
2018-07-03 |
Synergy Pharmaceuticals, Inc. |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
BR112017003745A2
(pt)
|
2014-08-29 |
2017-12-05 |
Tes Pharma S R L |
inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
JP2018507914A
(ja)
|
2015-03-09 |
2018-03-22 |
インテクリン・セラピューティクス・インコーポレイテッド |
非アルコール性脂肪肝疾患および/またはリポジストロフィーの処置のための方法
|
US11096924B2
(en)
|
2016-09-07 |
2021-08-24 |
Trustees Of Tufts College |
Combination therapies using immuno-dash inhibitors and PGE2 antagonists
|
TWI767945B
(zh)
|
2016-10-14 |
2022-06-21 |
義大利商Tes製藥(股份)責任有限公司 |
α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑
|
EP3551176A4
(de)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
Antidiabetische heterocyclische verbindungen
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
WO2018162722A1
(en)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Dpp-4 inhibitors for use in treating bone fractures
|
BR112019020485A2
(pt)
|
2017-04-03 |
2020-05-12 |
Coherus Biosciences, Inc. |
Agonista ppary para tratamento de paralisia supranuclear progressiva
|
PL3461819T3
(pl)
|
2017-09-29 |
2020-11-30 |
Probiodrug Ag |
Inhibitory cyklazy glutaminylowej
|
SG11202104550WA
(en)
|
2018-11-20 |
2021-05-28 |
Tes Pharma S R L |
INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
WO2021026047A1
(en)
|
2019-08-08 |
2021-02-11 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
EP4200295A1
(de)
|
2020-08-18 |
2023-06-28 |
Merck Sharp & Dohme LLC |
Bicycloheptanpyrrolidinorexinrezeptoragonisten
|
KR102567944B1
(ko)
*
|
2021-02-26 |
2023-08-18 |
(주)캔테라피 |
신규 아다만틸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도
|